OSE Immunotherapeutics to present at Biotech Showcase™

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
36
OSE Immunotherapeutics to present at Biotech Showcase™ 2019 Conference

During JP Morgan Healthcare Conference San Francisco, January 7-9, 2019

NANTES, France, Jan. 03, 2019 (GLOBE NEWSWIRE) --   OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), today announced that Alexis Peyroles, CEO, will present an overview of the Company’s business and will be available to participate in one-on-one meetings with investors at the Biotech Showcase™ to be held Jan. 7-9, 2019, in San Francisco.

The details of OSE Immunotherapeutics’ presentation are as follows:

Event:  Biotech Showcase™ 2019 Conference

Date: Tuesday, Jan. 8, 2019

Time: 11:00 a.m. PST

Location: Yosemite C (Ballroom level), Hilton San Francisco Union Square – 333 O’Farrell Street

The presentation will be webcast live and is accessible for 3 months: https://event.webcasts.com/starthere.jsp?ei=1...ac6dc1c6be    

ABOUT OSE Immunotherapeutics

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. The most advanced therapeutic-candidate, Tedopi ® , is a proprietary combination of 10 neo-epitopes aimed at stimulating T-lymphocytes and is currently in Phase 3 development in non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (anti PD-1 and anti PD-L1) and in Phase 2 testing in pancreatic cancer in combination with checkpoint inhibitor Opdivo®. FR104 (an anti-CD28 mAb) has successfully completed Phase 1 testing and has potential to treat autoimmune diseases. In April 2018, Boehringer Ingelheim and OSE signed a global license and collaboration agreement to develop preclinical checkpoint inhibitor OSE-172 (anti-SIRPa monoclonal antibody) in multiple cancer indications. OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) is partnered with Servier under an option agreement up to the completion of a Phase 2 clinical trial planned in autoimmune bowel diseases; in parallel, Servier plans a development in the Sjögren syndrome. OSE-127 is currently under Phase 1 clinical trial.

Click and follow us on Twitter and Linkedln

https://twitter.com/OSEIMMUNO https://www.linkedin.com/company/10929673

Contacts

OSE Immunotherapeutics Sylvie Détry Sylvie.detry@ose-immuno.com +33 143 297 857   French Media: FP2COM Florence Portejoie fportejoie@fp2com.fr +33 607 768 283 U.S. Media: LifeSci Public Relations Darren Opland, Ph.D. Darren@lifescipublicrelations.com +1 646 627-8387   U.S. and European Investors Chris Maggos chris@lifesciadvisors.com +41 79 367 6254

Forward-looking statements This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2018, including the annual financial report for the fiscal year 2017, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 64

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Pepsi Faces Georgia Labor Pressure Ahead of Strike

Updated Category News Views 73

A Pre-Dawn Labor Test Is Brewing in Georgia At 2:30 in the morning, nobody gathers outside a distribution center for the scenery. More than 100 Pepsi-Cola drivers from Atlanta and Lithonia are slated to meet Tuesday, November 24, at the Pepsi Distribution Center in Lithonia, Georgia, with Teamsters General President Sean M. O'Brien joining them. That hour matters. It puts...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 71

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 52

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 56

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 47

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading

Top 5 Most Recently Viewed Articles

Happy Day Brands and Sysco's Powerful Partnership for Change

Updated Category News Views 213

Happy Day Brands and Sysco Unite to Fight Hunger Happy Day Brands is stepping into the spotlight with an exciting partnership alongside Sysco that aims to nourish communities during a time when support is crucial. This collaboration is set to engage multiple states in a significant act of community service. Together, they will package over one million servings of...

Continue Reading
Upcoming Market Trends: The Influence of Trade Tensions

Updated Category News Views 245

Market Dynamics Shaped by Trade Tensions As we enter a new trading week, the economic landscape is painted with the resurgence of trade tensions. The discussions around tariffs, notably involving major economies, signal a return to aggressive trade policies that could influence market behavior. Understanding the Impact of Tariffs The reintroduction of tariffs has stirred...

Continue Reading
Carma HoldCo Invests in Mr. Charlie's for Plant-Based Growth

Updated Category News Views 150

Carma HoldCo Expands into Plant-Based Fast Food Market Carma HoldCo, renowned for its innovative brand portfolio, is making a significant leap into the plant-based quick-service restaurant (QSR) sector through a strategic investment in Mr. Charlie's Told Me So (TMS). This exciting partnership underlines the growing trend of health-conscious dining, particularly as...

Continue Reading
Advent Technologies to Showcase Innovative Maritime Solutions

Updated Category News Views 179

Advent Technologies Takes Center Stage at IEA Conference Advent Technologies Holdings, Inc. (NASDAQ: ADN) has announced that Dr. Emory De Castro, the Chief Technology Officer, will participate in the upcoming International Energy Agency (IEA) conference, set to occur in a prominent location soon. This event focuses on fuel cell applications within the maritime industry....

Continue Reading
Growing Demand in Polarized Sunglasses Market

Updated Category News Views 23

Polarized Sunglasses Gaining Traction Get this—polarized sunglasses are catching eyes like a bandwagon with NOS. Consumer365 just threw a nod at EZContacts for their impressive lineup of designer shades that promise to cut the glare while keeping those retinas comfy from the sun's death rays. Understanding the Hype Around Polarized Lenses Look, if you're fed up with...

Continue Reading